Hereditary angioedema: quality of life in Brazilian patients by Gomide, Maria Abadia Consuelo M. S. et al.
Hereditary angioedema: quality of life in Brazilian
patients
Maria Abadia ConsueloM. S. Gomide,I Eliana Toledo,II Solange Oliveira Rodrigues Valle,III Regis A. Campos,IV
Alfeu T. Franc¸a,III Nieves Prior Gomez,V Heitor Franco Andrade Jr.,VI Teresa Caballero,V Anete S. GrumachI,VII
I Faculdade de Medicina da Universidade de Sa˜o Paulo, Department of Dermatology, Sa˜o Paulo/SP, Brazil. IIUniversity of Sa˜o Jose´ do Rio Preto, Faculty of
Medicine, Brazil. III Federal University of Rio de Janeiro, Department of Immunology, Rio de Janeiro/RJ, Brazil. IV Federal University of Bahia, Department
of Clinical Immunology, Salvador/BA, Brazil. VHospital Universitario La Paz, Servicio de Alergia, Madrid, Spain. VI Faculdade de Medicina da Universidade
de Sa˜o Paulo, Department of Pathology, Sa˜o Paulo/SP, Brazil. VII Faculty of Medicine ABC, Santo Andre´/SP, Brazil.
OBJECTIVE: Hereditary angioedema is a serious medical condition caused by a rare autosomal dominant genetic
disorder and it is associated with deficient production or dysfunction of the C1 esterase inhibitor. In most cases,
affected patients experience unexpected and recurrent crises of subcutaneous, gastrointestinal and laryngeal
edema. The unpredictability, intensity and other factors associated with the disease impact the quality of life of
hereditary angioedema patients. We evaluated the quality of life in Brazilian hereditary angioedema patients.
METHODS: Patients older than 15 years with any severity of hereditary angioedema and laboratory
confirmation of C1 inhibitor deficiency were included. Two questionnaires were used: a clinical questionnaire
and the SF-36 (a generic questionnaire). This protocol was approved by the Ethics Committee of Hospital das
Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo.
RESULTS: The SF-36 showed that 90.4% (mean) of all the patients had a score below 70 and 9.6% had scores
equal to or higher than 70. The scores of the eight dimensions ranged from 51.03 to 75.95; vitality and social
aspects were more affected than other arenas. The internal consistency of the evaluation was demonstrated by
a Cronbach’s alpha value above 0.7 in seven of the eight domains.
CONCLUSIONS: In this study, Brazilian patients demonstrated an impaired quality of life, as measured by the SF-
36. The most affected domains were those related to vitality and social characteristics. The generic SF-36
questionnaire was relevant to the evaluation of quality of life; however, there is a need for more specific
instruments for better evaluation.
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& INTRODUCTION
Hereditary angioedema (HAE) is a serious medical
condition caused by a rare autosomal dominant genetic
disorder that is characterized by deficient production or
dysfunction of the C1 esterase inhibitor. The C1 inhibitor
acts as a regulatory protein in the complement, contact,
coagulation and fibrinolytic systems (1). The prevalence of
HAE is estimated to be between 1:10,000 and 1:50,000 (2).
Patients affected by HAE experience unexpected and
recurrent ‘‘attacks’’ of bradykinin-mediated edema. Edema
may occur in any part of the body but is most commonly
observed in the face, extremities, genitals, gastrointestinal
system and upper airways. Edema affecting the skin is
typically painless but may cause disfigurement or difficulty
driving or operating machinery. Gastrointestinal edema is
very painful and can lead to unnecessary laparotomy, while
upper airway edema can be life threatening due to swelling
of the tongue and larynx (3).
Some patients are able to identify triggering factors,
although in certain cases, no factors can be found. The most
common triggering factors are emotional stress, local
trauma, medical or dental procedures, infection, menses
and oral contraceptives (4).
These attacks are unpredictable, intense and vary in terms
of the site of edema. There is a potential risk of dying due to
asphyxiation. The efficacy of long-term prophylactic treat-
ment is inconsistent and it can cause side effects. All these
factors decrease the quality of life of this patient population.
However, few publications have described the quality of life
in patients with hereditary angioedema and no specific
questionnaire is currently available.
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The aim of the study was to evaluate the quality of life in
Brazilian patients with angioedema.
& METHODS
Ethical Aspects: The study protocol was approved by the
Ethics Committee of the Clinics Hospital of the Faculty of
Medicine of the University of Sa˜o Paulo. All patients signed
the informed consent form before any study procedures
took place.
Patient Population: Patients older than 15 years with any
severity of HAE and laboratory confirmation of C1 inhibitor
deficiency were included.
Data Collection: Two questionnaires were used: a clinical
questionnaire and the SF-36. The SF-36, a generic tool, was
previously culturally adapted and validated in Brazil (5).
The clinical questionnaire consisted of personal questions
and information about the disease; patients were asked
about their history of angioedema attacks in the previous six
months, treatment, side effects of medication, influence on
their social life, whether they had missed days of work or
school due to attacks, visits to emergency rooms and
psychological disturbances due to angioedema. A severity
score was calculated according to the data considered by
Agostoni et al. (3): adverse events from long-term therapy,
the frequency of attacks, absence from school and/or work
due to clinical symptoms, depression and anxiety, specific
treatment and need for hospitalization and/or ICU. The SF-
36 is a generic instrument that consists of 36 questions in
eight domains, which are pooled into two domains: physical
and mental.
The physical domain includes questions regarding the
following items: physical function (10 questions related to
routine activities), general health (five questions related to
the patient’s professional/educational life), pain (two
questions) and physical aspects (four questions related to
general well-being). The mental domain includes questions
about mental health (five items), vitality (four items), social
function (two items) and emotional well-being (three
items). A question asking the patient to compare his/her
current health to their health in the previous year is also
included.
Statistical Analysis: The data were evaluated with
Microsoft Excel 2007, SPSS 17 and Statistica 7.0. Endpoints
were considered statistically significant at p,0.05. The SF-36
internal reliability was tested using Cronbach’s alpha with a
range of zero to one, with zero indicating the absence of
correlation between items and one indicating perfect
correlation. A Cronbach’s alpha value equal to or greater
than 0.7 was considered acceptable.
& RESULTS
Thirty-five patients were included in the study. The
majority of patients were female (25 = 71.4%), from an urban
area (85.7%) and had an average level of education (42.9%)
and a medium-low socio-economic level (57.1%). The mean
age was 40.7 years (DP¡16.6 years).
In 54% of the patients, the disease was well controlled,
while 32% had mild symptoms and 14% had a moderate
degree of symptoms.
The SF-36 showed that 90.4% (mean) of patients had a
score below 70 and 9.6% had scores equal to or higher than
70. The scores of the eight dimensions applied in all patients
varied from 51.03 to 75.95; vitality and social aspects were
more affected. The internal consistency of the evaluation
was demonstrated by a Cronbach’s alpha above 0.7 in seven
of the eight domains (Table 1).
There were no differences between the mean scores of the
SF-36 in relation to gender, age, education level, or disease
severity.
& DISCUSSION
Although HAE is a rare disease, the patient burden is
similar to other more common chronic diseases (6); the
decrease in work productivity experienced by HAE patients
is comparable with that experienced by patients with
Crohn’s disease or severe asthma. In addition, HAE patients
must contend with the uncertainties of their disease. In our
case, it should be considered that Brazil has yet to invest in
the identification of these patients or access to therapy for
the attacks.
Danazol, the only medication supported by the Brazilian
government, is classified as a high-cost drug. Patients taking
androgens have reported more depressive symptoms and
reduced productivity levels compared to patients not taking
androgens (6). Androgens are often prescribed to patients
with higher attack frequencies and more severe disease
profiles (2).
Only a few studies have evaluated quality of life (QOL) in
HAE patients (6-8). In this study, Brazilian patients
exhibited an impaired QOL, as measured by the SF-36,
which is a generic questionnaire. The areas of their lives that
were most affected were those related to vitality and social
arenas. The patients felt tired, and their physical and
emotional conditions impacted their social and professional
Table 1 - Descriptive analysis of the SF-36 domains in 35 hereditary angioedema patients and Cronbach’s alpha values.
N Minimum Maximum Mean Median Standard deviation Cronbach’s alpha
Physical
functioning
35 15.00 100.00 75.57 85.00 22.61 0.90
Lim. physical
health
35 0.00 80.00 60.57 70.00 22.02 0.94
Body pain 35 0.00 100.00 58.10 52.00 30.15 0.90
General health
perception
34 20.00 90.00 59.26 40.00 18.71 0.84
Vitality 34 15.00 65.00 51.03 60.00 12.42 0.78
Social functioning 35 25.00 87.50 54.29 50.00 13.87 0.66
Lim. emotional
problems
35 0.00 100.00 75.95 83.30 25.14 0.90
Mental health 34 25.00 91.67 65.20 64.58 16.85 0.86
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activities. Poon et al. measured and compared Dermatology
Life Quality Index (DLQI) scores in different dermatological
conditions and included five patients with HAE (7). Bygum
et al. addressed the improvement in the QOL of seven HAE
patients related to medication used to ameliorate the edema
(8). Most recently, Lumry et al. (6) evaluated the impact of
HAE on QOL, applying one disease-specific survey and
three standardized instruments; approximately 19% of the
patients invited by the US HAE Association (n = 457)
responded to the questionnaires. Patients with HAE
reported decreased physical and mental health compared
to a normal population (p,0.001) for all subscales and
overall summary components. According to our data, the
social effects of HAE had a larger impact on patient QOL
than their physical condition.
Several questionnaires have been developed to evaluate
health-related quality of life. They provide information while
evaluating or comparing the effects of clinical interventions
or treatments, comparing differences between groups and
evaluating the impact of side effects and potential problems
demanding medical intervention. These questionnaires also
help to decide resource allocation (9). The generic SF-36
questionnaire is important in the evaluation of quality of life
in HAE patients; however, there is a need for studies using
disease-specific surveys with specific instruments to serve as
a point of comparison with generic questionnaires and
evaluate the correlation with clinical severity (10). A specific
HAE QOL questionnaire is currently being developed in
Spain and will soon be translated and validated in other
countries, including Brazil (11).
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